Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
05 Juli 2023 - 10:05PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, today announced that
Matthew Lang, J.D. has joined the executive management team as
Chief Business Officer. In this newly created role, Mr. Lang will
serve on Lyell’s executive committee and will be responsible for
Lyell’s legal, compliance, human resources, alliance management and
early commercialization teams. He will also serve as Lyell’s Chief
Legal Officer and Corporate Secretary.
“Matt is an experienced company builder who has
successfully led growth in complex organizations to realize the
value of innovative medicines for patients and shareholders,” said
Lynn Seely, M.D., Lyell’s President and CEO. “I am delighted to
welcome him to the team as we advance our mission of unlocking the
potential of cell therapy for patients with solid tumors.”
“I am excited to join Lyell at a time when the
team has progressed two product candidates into clinical
development, with initial clinical data expected next year,” said
Mr. Lang, Lyell’s Chief Business Officer. “Lyell’s pioneering
science, diverse product pipeline and experienced leadership
provide a unique opportunity to work as part of a team focused on
delivering potentially transformative medicines for patients.”
Mr. Lang was previously Chief Administrative and
Legal Officer and Corporate Secretary at Myovant Sciences where he
built and led numerous functions at various stages including legal,
compliance, human resources, alliance management, corporate
communications, and risk management and helped build and lead the
company through Phase 3 clinical development and global approval
and commercialization of Myfembree® and
Orgovyx®. While at Myovant, he negotiated numerous
US and European co-development, licensing and commercialization
deals as well as multiple financing and acquisition transactions
totaling over $7.5 billion. Mr. Lang also served as the Managing
Director and General Manager of Myovant’s European operations in
Basel Switzerland where he was responsible for all aspects of
Myovant’s ex-US business operations. Prior to Myovant, Mr. Lang
held positions as Vice President, Head of Global Litigation,
Investigations, Employment Law and Information Governance at Gilead
Sciences, Inc. At Gilead, in addition to leading core functions
within the legal department, Mr. Lang was a member of the company's
corporate operating group, global legal leadership team, and global
compliance committee. Prior to Gilead, Mr. Lang was an attorney at
Dechert LLP in New York City. Mr. Lang received his BA in
Classical Studies from Queen's University at Kingston
in Canada and his J.D. from the University of
Pennsylvania Law School.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a diverse pipeline of cell therapies for patients
with solid tumors. The technologies powering its product candidates
are designed to address barriers that limit consistent and
long-lasting responses to cell therapy for solid tumors: T-cell
exhaustion and lack of durable stemness, which includes the ability
to persist and self-renew to drive durable tumor cytotoxicity.
Lyell is applying its proprietary ex vivo genetic and epigenetic
reprogramming technologies to address these barriers in order to
develop new medicines with improved durable clinical outcomes.
Lyell is based in South San Francisco, California with facilities
in Seattle and Bothell, Washington. To learn more, please visit
www.lyell.com.
Contact:Ellen RoseSenior Vice
President, Communications and Investor
Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024